创始人与科学顾问
柏全生物的创始人许杰博士是肿瘤学领域的资深专家，长期致力于肿瘤免疫治疗新靶点的发现与相关药物开发，揭示了CD3L1、Galectin-8等全新的免疫检查点，相关研究成果发表在Cell等国际顶级期刊，在突破性科学发现的基础上开发的全新靶点（first-in-class）抗体药物，已获得中国、美国IND批准，正式进入临床开发阶段。
代表论文：
1. ITPRIPL1 binds CD3ε to impede T-cell activation and enable
tumor immune evasion. Cell, 2024 Apr 5:S0092-8674(24)00310-6
2. Discovery of galectin-8 as an LILRB4 ligand driving
M-MDSCs defines a class of antibodies to fight solid tumors. Cell
Reports Medicine, 2024,5(1):101374
3. HIP1R targets PD-L1 to lysosomal degradation to alter T
cell-mediated cytotoxicity. Nature Chemical Biology, 2019 (1):
42~50.
4. Inhibiting PD-L1 palmitoylation enhances T-cell immune
responses against tumours, Nature Biomedical Engineering，2019; 3(5):414.
5. A Designed Peptide Targets Two Types of Modifications of
p53 with Anti-cancer Activity, Cell Chemical Biology, 2018, 25(6):
761~774
主编专著：
《Regulation of Cancer Immune Checkpoints》 Springer Book. 2020 ISBN: 9811532656
所获人才项目：
国家高层次人才领军项目
国家高层次人才青年项目
